Conditions: Diabetic Nephropathies
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 823
Healthy volunteers: no

Brief summary:
To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy. These treatment doses were compared to placebo.

Detailed description:

Arms:
arm 1: 1.25 mg dose oral once daily for 90 days arm 2: 2.5 mg dose oral once daily for 90 days arm 3: 5 mg dose oral once daily for 90 days arm 4: 7.5 mg dose oral once daily for 90 days arm 5: 10 mg dose oral once daily for 90 days arm 6: 15 mg dose oral once daily for 90 days arm 7: 20 mg dose oral once daily for 90 days arm 8: Placebo oral dose once daily for 90 days

Interventions: intervention 1: Finerenone (BAY94-8862) intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: